文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病与外周动脉疾病患者中的血小板活性及心血管风险

Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease.
PubMed 文献 · Kidney Int Rep · 2022-08-04

本研究为前瞻性队列研究,纳入285例接受下肢血运重建的外周动脉疾病成人,比较合并慢性肾脏病(CKD,eGFR<60 ml/min per 1.73 m²)与不合并CKD者的血小板活性及心血管事件。中位随访18个月,CKD患者对ADP、5-羟色胺、肾上腺素及花生四烯酸+体外阿司匹林刺激的血小板聚集均更高(P<0.05),校正后心肌梗死风险升高(aHR 2.2,95%CI 1.02-4.9),主要不良心血管事件风险升高(aHR 1.9,95%CI 1.2-3.3);血小板聚集介导了CKD相关心血管事件超额风险的7%至26%。

要点

  • 在因外周动脉疾病行下肢血运重建的患者中,40%(113/285)合并CKD(eGFR<60 ml/min per 1.73 m²)。
  • 合并CKD者经ADP、5-羟色胺、肾上腺素及花生四烯酸+体外阿司匹林刺激的血小板聚集均高于不合并CKD者(各项P<0.05)。
  • 校正后CKD与心肌梗死(aHR 2.2,95%CI 1.02-4.9)及主要不良心血管事件(aHR 1.9,95%CI 1.2-3.3)风险升高相关。

核心结论

  • 在接受下肢血运重建的外周动脉疾病患者中,CKD与血小板活性增高相关,且血小板活性部分介导了CKD相关的心血管风险升高。

研究设计与样本

  • 研究为前瞻性队列研究(Platelet Activity and Cardiovascular Events研究),纳入接受下肢血运重建的外周动脉疾病成人。
  • 共285例受试者,其中113例(40%)合并CKD(eGFR<60 ml/min per 1.73 m²),采用光透射聚集法(LTA)在次最大剂量激动剂刺激下测定血小板活性,中位随访18个月观察心血管事件。

主要发现

  • 合并CKD者经ADP、5-羟色胺、肾上腺素及花生四烯酸+体外阿司匹林刺激的血小板聚集均高于不合并CKD者(各项P<0.05)。
  • 多变量校正后,合并CKD者发生心肌梗死的风险为不合并CKD者的2.2倍(aHR 2.2,95%CI 1.02-4.9)。
  • 多变量校正后,合并CKD者发生主要不良心血管事件的风险为不合并CKD者的1.9倍(aHR 1.9,95%CI 1.2-3.3)。
  • 次最大剂量激动剂刺激下的血小板聚集介导了CKD相关心血管事件超额风险的7%至26%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Platelet dysfunction and cardiovascular risk are well-recognized features of chronic kidney disease (CKD). Platelets drive the development and progression of cardiovascular disease (CVD). The relationships between kidney function, platelet activity, and cardiovascular risk are poorly defined. METHODS: We compared platelet activity and incident cardiovascular events by CKD status (estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m2) using data from the Platelet Activity and Cardiovascular Events study, a prospective cohort study that enrolled adults with peripheral artery disease (PAD) undergoing lower extremity revascularization. Platelet activity was measured using light transmission aggregometry (LTA) in response to submaximal dose agonist stimulation, and the subjects were followed for incident adverse cardiovascular events for a median of 18 months. RESULTS: Overall, 113 of 285 (40%) subjects had CKD. Subjects with, versus without, CKD had higher platelet aggregation in response to stimulation with adenosine diphosphate (ADP), serotonin, epinephrine, and arachidonic acid (AA) + ex vivo aspirin (P < 0.05 for each). Following multivariable adjustment, subjects with CKD had elevated risk for myocardial infarction (MI) (adjusted hazard ratio 2.2, 95% confidence interval [1.02-4.9]) and major adverse cardiovascular events (MACE) (1.9 [1.2-3.3]) compared to those without CKD. Platelet aggregation in response to submaximal dose agonist stimulation mediated 7% to 26% of the excess risk for cardiovascular events associated with CKD. CONCLUSION: Among subjects with PAD undergoing lower extremity revascularization, CKD is associated with increased platelet activity that mediates, in part, elevated cardiovascular risk.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cofer LB, Soomro QH, Xia Y, et al. Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease. Kidney Int Rep. 2022. PMID: 36217517. doi:10.1016/j.ekir.2022.07.169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。